Medical affairs outsourcing to double to $3.6Bn by 2033: Market.us
NEW YORK, UNITED STATES — The global medical affairs outsourcing market is projected to grow from $1.8 billion in 2023 to $3.6 billion by 2033, driven by the increasing complexity of clinical trials and regulatory requirements, according to Market.us.
Pharmaceutical firms account for 48.9% of outsourcing demands, opting to scale cost-effective solutions through specialized firms to meet requirements for medical writing, safety monitoring, and the generation of real-world evidence.
Pharma giants drive outsourcing boom
The medical writing segment itself accounts for 37.4% of the market, highlighting a key market factor that demands precision in addressing Food and Drug Administration (FDA) and European Medicines Agency (EMA) compliance within the industry.
Cost pressures are accelerating the shift because having in-house teams is too costly, particularly for smaller firms.
Outsourcing can be flexible, with partners such as Freyr, a North American provider of compliance software, offering AI-driven analytics and a cloud-based stack to reduce operational load.
With drug approvals booming, pharmaceutical players can concentrate on research and development processes without having to deal with complex medical communications, thanks to outsourcing.
Asia Pacific surges on pharma partnerships, cost edge
Being managed with the help of strict policies and technology-based solutions proposed by companies such as Freyr, which was rated in the list of the “10 Best Technology Solution Providers” by USA-9 Technology Magazine, North America established its 2023 market revenue of 41.2%.
The region’s dominance in healthcare systems is based on its highly developed healthcare infrastructure, high levels of investment in research and development (R&D), and outsourcing, which keeps pace with changes in regulations.
In the meantime, the region with the largest compound annual growth rate (CAGR) is the Asia Pacific, driven by alliances such as the one between Pfizer and India-based NIPER Ahmedabad, which has been ongoing since 2024, aimed at aiding healthcare startups.
The governments of India, China, and the Philippines are facilitating clinical trials by providing experienced manpower at low costs.
The use of time zone working and multilingual medical teams has enabled local outsourcing partners to provide services globally, making the region a hub for medical writing and real-world data projects.
